Antibody phage-display technology is a powerful tool for the identification and characterization of novel antibodies and antibody-antigen interactions. Conventional approaches require multiple rounds of colony selection based on binding specificities, along with the time-consuming and labor-intensive processes of colonnies plating and picking followed by Sanger sequencing. Although this approach demand substantial time and resources, the accurate quantification of full-length diversity remains a challenge. Additionally, they often fail to recover low-frequency binders effectively, leading to incomplete or imperfect results. This becomes even more pronounced in case of multiple DNAs or multiple priming events. In large antibody libraries, these challenges are amplified, making it difficult to achieve precise and reliable outcomes in a cost-efficient and timely manner

SMARTLife Biosciences established and validated the DNA Pool Long Read SMARTSeq service to improve the detection of rare antibody, enhancing the likelihood of discovering valuable antibodies for therapeutic or diagnostic.

DNA Pool Long Read SMARTSeq is suitable for simple to complex mixtures. We produce 5,000 reads / sample or multiple of 5,000 reads from each vial depending on the starting material available.

Long Read Nanopore sequencing is performed on the native DNA from your vial containing pooled DNAs (phagemides or amplicons). This streamlined process provides a much more efficient and scalable approach to antibody discovery tha Sanger sequencing, especially when dealing with large-scale libraries..

Our local laboratories perform Long Read SMARTSeq sequencing directly on native DNA from your vial.

Results are available in 48 to 72h (depending on samples bacth size).

The sequencing run is calibrated to generate 5,000 Long Reads / sample or multiple of 5,000 reads depending on the DNA mixture complexity ( depending on starting material available in the vial).

Thanks to the long readlength (from 100 bp to 300 kb), this service allows for the direct sequencing of full-length antibody sequences, ensuring accurate identification of both VH and VL chains, and the complete CDR regions, leading  to more comprehensive, accurate, and efficient discovery of antibodies with relevant target-binding properties.